0001140361-19-013355.txt : 20190724
0001140361-19-013355.hdr.sgml : 20190724
20190724160108
ACCESSION NUMBER: 0001140361-19-013355
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190722
FILED AS OF DATE: 20190724
DATE AS OF CHANGE: 20190724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 19970966
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
form4.xml
FORM 4
X0306
4
2019-07-22
true
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
true
Common Stock
2019-07-22
4
C
0
1785714
A
1785714
I
See Footnote
Series B Preferred Stock
2019-07-22
4
C
0
12500000
0
D
Common Stock
1785714
0
I
See footnote
On July 22, 2019 upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date.
The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
/s/ Victoria Whyte
Authorized Signatory
GlaxoSmithKline plc
2019-07-24